Navigation Links
Compounds could be new class of cancer drugs
Date:2/3/2009

A team of Vanderbilt University Medical Center investigators has developed a group of chemical compounds that could represent a new class of drugs for treating cancer.

The compounds are the first selective inhibitors of the protein phospholipase D (PLD), an enzyme that has been implicated in multiple human cancers including breast, renal, gastric and colorectal.

The new inhibitors, reported in the February issue of Nature Chemical Biology, block the invasive migration of breast cancer cells, supporting their further development as antimetastatic agents. They will also be useful tools for understanding the complex roles of PLD in cellular physiology, said H. Alex Brown, Ph.D., professor of Pharmacology and one of the team leaders.

"PLD is associated with many fundamental cellular processes like secretion, migration, growth and proliferation. But the absence of selective inhibitors has really interfered with the ability of biologists to study this important enzyme," Brown said.

There are two related "isoforms" of PLD: PLD1 and PLD2. Both PLD enzymes produce phosphatidic acid, a key lipid metabolic and signaling molecule. But whether the two PLDs have different roles is an open question, one that the new isoform-selective inhibitors can now be used to address.

Brown and colleagues had discovered that PLD was important to the invasive migration of breast cancer cells in culture using a genetic tool called small interfering RNA (siRNA).

"When we had evidence from siRNA and other methods that blocking PLD resulted in dramatic effects of blocking metastatic invasion of breast cancer cells, we were highly motivated to attempt to make isoform-selective inhibitors," Brown said.

Craig Lindsley, Ph.D., a medicinal chemist who joined the Vanderbilt faculty after five years at Merck Research Laboratories, and his group used a previously described PLD inhibitor as a starting point for a chemistry process called diversity-oriented synthesis.
'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
2. 2 new compounds show promise for eliminating breast cancer tumors
3. Two new compounds show promise for eliminating breast cancer tumors
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
6. New $11 million center to speed production of new compounds for drug discovery
7. Discovery of natural compounds that could slow blood vessel growth
8. Duke team finds compounds that prevent nerve damage
9. New study shows compounds from soy affect brain and reproductive development
10. Natural compounds in cocoa tied to blood flow improvements for adults with type 2 diabetes
11. Green tea compounds beat OSA-related brain deficits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Seventy-eight microbiologists have been elected to Fellowship ... of the Academy are elected annually through a ... of scientific achievement and original contributions that have ... representing all subspecialties of microbiology, including basic and ...
... Humans are sustained by a multitude of processes ... are called "ecosystem services," and include products like clean ... crops and spices. On Thursday, March 4, the ... "Ecosystem Services in a Changing World: Perspectives from Long-Term ...
... The Proceedings of the National Academy of Sciences ... PNAS papers to receive the 2009 Cozzarelli Prize, an ... by the National Academy of Sciences. Papers selected for ... articles published by PNAS in 2009 and represent ...
Cached Biology News:78 scientists elected to the American Academy of Microbiology 278 scientists elected to the American Academy of Microbiology 378 scientists elected to the American Academy of Microbiology 4NSF forum to address 'ecosystem services' in a changing world 2PNAS announces 6 2009 Cozzarelli Prize recipients 2
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... de la santé, publie ses résultats pour le ... Brandicourt commente les résultats. Visionner ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire ... - Moteurs de croissance ...
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... - BioAmber Inc. (NYSE: BIOA ) today announced that ... has resigned.  The Company has hired Andrew Ashworth ... December 2014, as full time interim CFO and has ... Andy Ashworth began his employment today, to ... Andy was the Company,s CFO from September 2011 to ...
Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... 1 SynCo Bio Partners B.V., the,expert in long ... has expanded its business into a new geographical,market, with ... biotherapeutic,for an emerging Japanese pharmaceutical company. , ... live biotherapeutic,based anticancer drug. The project will first involve ...
... , , FORT LAUDERDALE, Fla., ... a leader in integrated electronic data capture (EDC) ... fastest growing companies in the EDC marketplace, announced today that ... have joined its rapidly expanding partnership program, the CRO Preferred ...
... , , SOUTH SAN FRANCISCO, ... changing the paradigm of drug discovery and development through the ... Plunkett, Ph.D., as vice president and chief financial officer. , ... term success, and Matt,s career over the last decade has given ...
Cached Biology Technology:SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer 2
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... Primer is designed for sequencing inserts cloned ... V2051, V2061). The primer hybridizes upstream of ... approximately 4050 base pairs upstream of the ... to determine if an insert is cloned ...
Request Info...
...
Biology Products: